Wall Street analysts expect that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will report earnings of ($0.25) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with estimates ranging from ($0.27) to ($0.22). Infinity Pharmaceuticals posted earnings of ($0.46) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 45.7%. The business is expected to report its next quarterly earnings report on Tuesday, March 13th.
On average, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.93) per share for the current fiscal year, with EPS estimates ranging from ($0.95) to ($0.90). For the next financial year, analysts forecast that the business will report earnings of ($1.07) per share, with EPS estimates ranging from ($1.10) to ($1.04). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Infinity Pharmaceuticals.
Separately, ValuEngine cut shares of Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.
Large investors have recently modified their holdings of the stock. Millennium Management LLC lifted its stake in shares of Infinity Pharmaceuticals by 105.3% in the 4th quarter. Millennium Management LLC now owns 1,198,854 shares of the biotechnology company’s stock worth $2,434,000 after acquiring an additional 614,806 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Infinity Pharmaceuticals by 102.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 150,375 shares of the biotechnology company’s stock worth $305,000 after acquiring an additional 75,980 shares during the period. BVF Inc. IL lifted its stake in shares of Infinity Pharmaceuticals by 24.2% in the 4th quarter. BVF Inc. IL now owns 9,766,508 shares of the biotechnology company’s stock worth $19,826,000 after acquiring an additional 1,900,400 shares during the period. Geode Capital Management LLC lifted its stake in shares of Infinity Pharmaceuticals by 22.2% in the 4th quarter. Geode Capital Management LLC now owns 325,567 shares of the biotechnology company’s stock worth $660,000 after acquiring an additional 59,064 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of Infinity Pharmaceuticals by 654.7% in the 4th quarter. Wells Fargo & Company MN now owns 105,136 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 91,206 shares during the period. Hedge funds and other institutional investors own 54.69% of the company’s stock.
Shares of Infinity Pharmaceuticals (NASDAQ INFI) opened at $1.87 on Thursday. The firm has a market cap of $94.79, a price-to-earnings ratio of -1.64 and a beta of 2.82. Infinity Pharmaceuticals has a 52 week low of $0.93 and a 52 week high of $3.84.
ILLEGAL ACTIVITY WARNING: “Infinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.25 Per Share” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/15/infinity-pharmaceuticals-inc-infi-expected-to-post-earnings-of-0-25-per-share.html.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.